heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate
• 英文别名: Heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate；nonyl 8-[2-acetyloxyethyl-(8-heptadecan-9-yloxy-8-oxooctyl)amino]octanoate
• 化学式: C₄₆H₈₉NO₆
• 分子量: 752.216
• InChiKey: CDLJTVGOULEJFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.1
• 重原子数：
  53
• 可旋转键数：
  45
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-壬醇 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
  [FR] COMPOSÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES

  摘要：

  公开号：

  WO2017049245A3

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS D'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2018170306A1

  公开（公告）日：2018-09-20

  The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及新型脂质和相关组合物。纳米粒子组合物包括一种新型脂质以及额外的脂质，如磷脂、结构脂质和PEG脂质。纳米粒子组合物还包括治疗和/或预防措施，如RNA，在将治疗和/或预防措施传递给哺乳动物细胞或器官方面非常有用，例如，调节多肽、蛋白质或基因表达。
• [EN] POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME<br/>[FR] POLYNUCLÉOTIDES CODANT POUR JAGGED1 POUR LE TRAITEMENT DU SYNDROME D'ALAGILLE
  申请人：MODERNATX INC

  公开号：WO2017201342A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof, functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

  该发明涉及用于治疗艾拉吉尔综合征（ALGS）的mRNA疗法，该发明中使用的mRNA，在体内给予时，编码JAGGED 1（JAG1）、其同工异构体、其功能性片段以及包含JAG1的融合蛋白，该发明的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的有效传递，当向受试者施用时。该发明的mRNA疗法增加和/或恢复受试者中JAG1表达和/或活性的不足水平。该发明的mRNA疗法进一步降低与受试者中JAG1活性不足相关的有毒代谢物水平。
• [EN] MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF<br/>[FR] ARNM CODANT DES POLYPEPTIDES DE MODULATION IMMUNITAIRE ET LEURS UTILISATIONS
  申请人：MODERNA TX INC

  公开号：WO2021076805A1

  公开（公告）日：2021-04-22

  The disclosure features lipid nanoparticle (LNP) compositions comprising immune modulating polypeptides and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune modulating polypeptides, e.g., interleukin 2 (IL- 2) and/or granulocyte macrophage colony stimulating factor (GM-CSF). The LNP compositions of the present disclosure can stimulate T regulatory cells, e.g., increase the level and/or activity of T regulatory cells in vivo or ex vivo.

  披露了包含免疫调节多肽的脂质纳米粒子（LNP）组合物及其用途。本公开的LNP组合物包括编码免疫调节多肽的mRNA治疗药物，例如白细胞介素2（IL-2）和/或粒细胞巨噬细胞集落刺激因子（GM-CSF）。本公开的LNP组合物可以刺激T调节细胞，例如在体内或体外增加T调节细胞的水平和/或活性。
• COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20220409536A1

  公开（公告）日：2022-12-29

  The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及新型脂质和相关组合物。纳米粒子组合物包括一种新型脂质以及其他脂质，例如磷脂、结构脂质和PEG脂质。纳米粒子组合物进一步包括治疗和/或预防剂，例如RNA，可用于将治疗和/或预防剂传递到哺乳动物细胞或器官中，例如调节多肽、蛋白质或基因表达。
• RESPIRATORY VIRUS VACCINES
  申请人：ModernaTX, Inc.

  公开号：EP3718565A1

  公开（公告）日：2020-10-07

  The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

  本公开涉及呼吸道病毒核糖核酸（RNA）疫苗和联合疫苗，以及使用这些疫苗和包含这些疫苗的组合物的方法。